FDA Inspection
Recipharm Pharmaservices Private LimitedRecipharm Pharmaservices Private Limited – FDA Inspection, Feb 1, 2019
Record Details
This FDA Inspection record concerns Recipharm Pharmaservices Private Limited, with an inspection on February 1, 2019, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · ff968ebc-40dd-49c7-84d3-8d2080f8bc3c
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1079034
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
3- 21 CFR 211.110(a)Control procedures to monitor and validate performance
- 21 CFR 211.113(a)Procedures for non-sterile drug products
- 21 CFR 211.63Equipment Design, Size and Location
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Recipharm Pharmaservices Private Limited
8| Date | Classification | Office | Project area |
|---|---|---|---|
| March 22, 2024 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| February 13, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 7, 2018 | VAI | Office of Inspections and Investigations | Generic Drug Evaluation |
| May 11, 2018 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 14, 2017 | Not classified | Office of Inspections and Investigations |
Other documents for Recipharm Pharmaservices Private Limited
- FDA Inspection 1232473 - 2024-03-22
- FDA Inspection 1119410 - 2020-02-13
- FDA Inspection 1075220 - 2018-12-07
- FDA Inspection 1053644 - 2018-05-11
- FDA Inspection 1037690 - 2017-12-14
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.